You are here: Industry Insights > Bharat Biotech

News List

Halt Bharat Biotech’s COVAXIN trial in Bhopal: Civil society organisations expresspharma
January 15, 2021
These organisations state that unethical conduct, protocol violations in a clinical trial where an apex government body is a co-sponsor is particularly alarming.
Bharat Biotech ships out COVAXIN to 11 cities expresspharma
January 14, 2021
It has received a government purchase order for 55 lakh doses, the company has also donated 16.5 lakh doses to the Government of India.
Bharat Biotech signs deal with Precisa Medicamentos for COVAXIN supply to Brazil expresspharma
January 13, 2021
Supplies will be prioritised for the public market through a direct procurement by the Government of Brazil, private market will get the vaccine after receipt of market authorisation from ANVISA.
Bharat Biotech to start Phase-1 trials of intranasal COVID-19 vaccine in Feb-March 2021 expresspharma
January 11, 2021
The company is developing this a single dose intranasal vaccine for COVID-19 in partnership with Washington University School of Medicine in St Louis.
Covaxin trial participant’s death unrelated to ‘vaccine or placebo’: Bharat Biotech expresspharma
January 11, 2021
He was reported to be healthy in follow-up calls post seven days of his dosing and no adverse reaction was observed or reported, claims company.
Bharat Biotech to make 700 million doses in 2021 expresspharma
January 06, 2021
Dr Krishna Ella, Chairman and MD Bharat Biotech said that Covaxin trials '200 per cent honest'.
SII, Bharat Biotech jointly pledge to work for smooth roll out of COVID-19 vaccines expresspharma
January 06, 2021
They said that the important task in front of them is saving the lives and livelihoods of populations in India and the world.
SEC recommends EUA for Covaxin from Bharat Biotech expresspharma
January 04, 2021
The expert panel deliberated on Bharat Biotech’s EUA application after it submitted additional data, facts and analysis after Friday's review meeting.
COVAXIN clinical trials recruit 23,000 subjects expresspharma
January 04, 2021
COVAXIN has been evaluated in approximately 1000 subjects in Phase I and Phase II clinical trials, with promising safety and immunogenicity results.
DCGI approves Covishield and Covaxin for restricted emergency use in India expresspharma
January 04, 2021
DCGI’s decision comes after the Subject Expert Committee of CDSCO met on January 1-2, 2021 and recommended the grant of permission for restricted emergency use of these vaccines.

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page